Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Fibrogen Inc Shares Up 5.5% Since SmarTrend's Buy Recommendation (FGEN)

SmarTrend identified an Uptrend for Fibrogen Inc (NASDAQ:FGEN) on June 16th, 2020 at $39.74. In approximately 3 months, Fibrogen Inc has returned 5.51% as of today's recent price of $41.93.

FGEN : 42.79 (-2.75%)
FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer

FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging...

FGEN : 42.79 (-2.75%)
Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.

JNJ : 144.67 (+0.16%)
AMGN : 240.32 (-0.94%)
AKBA : 2.46 (-3.15%)
FGEN : 42.79 (-2.75%)
Thinking about trading options or stock in FibroGen Inc, Beyond Meat, Eli Lilly, Bank of America, or Tesla?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FGEN, BYND, LLY, BAC, and TSLA.

BAC : 23.34 (+0.34%)
LLY : 148.81 (-0.67%)
FGEN : 42.79 (-2.75%)
FibroGen to Present at Upcoming Investor Conferences

FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:

FGEN : 42.79 (-2.75%)
Chart Analysis: FibroGen (FGEN) Nears a Support Level

FibroGen (FGEN) is nearing a support level. Will it fall to $40? Learn when to enter a short position. Over the past couple of months a key support level was formed in the chart of FibroGen Inc. (...

FGEN : 42.79 (-2.75%)
SmarTrend Watching for Potential Rebound in Shares of Fibrogen Inc After 4.57% Loss

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $42.23 to a high of $44.87. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $43.77...

FGEN : 42.79 (-2.75%)
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids...

FGEN : 42.79 (-2.75%)
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 42.79 (-2.75%)
FibroGen Reports Second Quarter 2020 Financial Results

- Strong Second Quarter China Roxadustat Net Sales of $15.7 million -

FGEN : 42.79 (-2.75%)
SYBX : 2.00 (+3.63%)
FibroGen Announces New Appointments to its Board of Directors

- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) -

FGEN : 42.79 (-2.75%)
SYBX : 2.00 (+3.63%)
KKR Acquires Stake in First Gen through Voluntary Tender Offer

Global investment firm KKR today announced that, following the completion of the voluntary tender offer period by Valorous Asia Holdings (the "Offeror"), an entity owned by KKR investment funds, the Offeror...

FGEN : 42.79 (-2.75%)
KKR : 33.06 (-3.05%)
Theravance Doses First Patient in Phase II Coronavirus Study

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

AZN : 54.17 (-2.68%)
RHHBY : 44.7000 (-0.36%)
TBPH : 15.53 (-3.78%)
FGEN : 42.79 (-2.75%)
FibroGen Begins Phase II Study for Acute Coronavirus in US

FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.

AZN : 54.17 (-2.68%)
RHHBY : 44.7000 (-0.36%)
AMGN : 240.32 (-0.94%)
FGEN : 42.79 (-2.75%)
Fibrogen Inc Rises 3.81% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $42.58 to a high of $43.84. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $42.30...

FGEN : 42.79 (-2.75%)
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients...

FGEN : 42.79 (-2.75%)
FibroGen Appoints Thane Wettig as Chief Commercial Officer

FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen's commercialization efforts, leveraging more...

FGEN : 42.79 (-2.75%)
Look for Shares of Fibrogen Inc to Potentially Pullback after Yesterday's 1.51% Rise

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $39.82 to a high of $41.15. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $40.63...

FGEN : 42.79 (-2.75%)
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ALDX : 6.77 (-0.15%)
FGEN : 42.79 (-2.75%)
FibroGen Initiates Phase II/III Study in Severe Coronavirus

FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.

AZN : 54.17 (-2.68%)
RHHBY : 44.7000 (-0.36%)
AMGN : 240.32 (-0.94%)
FGEN : 42.79 (-2.75%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar